USD 12.92
↑ 0.48 (3.86%)
| ticker | 1 day return % | 1 week return % | 1 month return % | 3 months return % | 6 months return % | 1 year return % | 3 years return % | 5 years return % | 10 years return % | maximum return % |
|---|---|---|---|---|---|---|---|---|---|---|
| SIBN | 3.9 | -17.0 | -2.3 | -6.8 | -14.6 | -26.9 | -41.4 | -26.3 | -35.6 | -35.6 |
| S&P 500 | -1.3 | -2.3 | 0.5 | 5.7 | 10.8 | 30.2 | 24.9 | 88.0 | 187.6 | 33142.5 |
Our interactive price chart includes various drawing tools to help you analyze the product more effectively. Below is a quick guide on how to use these tools: Full Guideline
Feel free to experiment with these tools to enhance your technical analysis. Remember, any drawings you make are temporary and will be lost upon refreshing the page unless saved as an image using the 'Camera' icon.
Get instant AI-powered professional insights on prices:
💡Generate AI Technical Analysis ReportA Multi-Interval Candlestick Chart displays the price movements of an asset over different time intervals. Each candlestick represents the open, high, low, and close prices for a specific interval. The chart can be used to identify trends and patterns in price movements.
| Attribute | Value |
|---|---|
| symbol | SIBN |
| name | SI-BONE, Inc. |
| price | 12.92 |
| changes percentage | 3.86 |
| change | 0.48 |
| day low | 12.32 |
| day high | 13.11 |
| year high | 21.70 |
| year low | 11.76 |
| market cap | 541841544 |
| price avg 50 | 14.07 |
| price avg 200 | 15.23 |
| exchange | NASDAQ |
| volume | 592914 |
| avg volume | 366979 |
| open | 12.54 |
| previous close | 12.44 |
| eps | -1 |
| pe | -12.92 |
| earnings announcement | 2024-11-12T05:00:00.000+0000 |
| shares outstanding | 41938200 |
| timestamp | 2024-11-15 21:00:01 |
We derive the score of a company's financial statements by evaluating the weighted average sentiment across key within the statements. The cumulative score, normalized to a sum of 1, serves as a metric for assessing the company's performance during the specified period. A higher score indicates stronger performance. However, it's crucial to note that while this score provides valuable insights, it is just one of many factors to consider when making informed investment decisions. A holistic evaluation, considering various aspects of the company's financial health and market conditions, is essential for a well-rounded investment strategy.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0001459839 | |||
| revenue | 138886000 | 106409000 | 30.52 |
| gross profit | 109420000 | 90704000 | 20.63 |
| gross profit ratio | 0.79 | 0.85 | -7.57 |
| research and development expenses | 15028000 | 13627000 | 10.28 |
| operating expenses | 156351000 | 150313000 | 4.02 |
| interest income | 6916000 | 1304000 | 430.37 |
| interest expense | 3462000 | 2819000 | 22.81 |
| ebitda | -34446000 | -54985000 | 37.35 |
| ebitdaratio | -0.25 | -0.55 | 54.84 |
| operating income | -46931000 | -59609000 | 21.27 |
| operating income ratio | -0.34 | -0.56 | 39.68 |
| net income | -43336000 | -62903000 | 31.11 |
| net income ratio | -0.31 | -0.59 | 47.22 |
| eps | -1.13 | -1.84 | 38.59 |
Revenue Growth: revenue increased to 139 million in 2023 from 106 million in 2022 representing a change of 30.52%. This indicates a sales growth, which is a positive sign for the company.
Gross Profit: Gross Profit increased to 109 million in 2023 from 91 million in 2022 representing a change of 20.63%. This indicates a sales profitability growth, which is a positive sign for the company.
Research and Development (R&D) Expenses: R&D Expenses increased to 15 million in 2023 from 14 million in 2022 representing a change of 10.28%. This shows that the company continues to invest in innovation and product development, which is crucial for long-term growth.
Earnings per Share (EPS): EPS increased to -1.13 in 2023 from -1.13 in 2022 representing a change of 38.59%. This indicates that the company's earnings are increasing and it is becoming more profitable on a per-share basis.
Operating Expenses: Operating Expenses increased to 156 million in 2023 from 150 million in 2022 representing a change of 4.02%. The increase in operating expenses can be attributed to various factors such as marketing, administrative costs, and investments in infrastructure. It's important to monitor if these expenses are growing at a sustainable rate compared to revenue.
EBITDA: EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) decreased to -34 million in 2023 from -55 million in 2022 representing a change of 37.35%. The decrease in EBITDA indicates declined operational efficiency and profitability.
Operating Income: Operating income decreased to -47 million in 2023 from -60 million in 2022 representing a change of 21.27%. The decrease in operating income indicates worse operational performance and decreased profitability.
Net Income: Net income decreased to -43 million in 2023 from -63 million in 2022 representing a change of 31.11%. The decrease in net income shows worsen profitability and indicates that the company is generating less profit for each dollar of revenue.
| 2024Q3 | 2024Q2 | Q/Q change % | |
|---|---|---|---|
| 0001459839 | |||
| revenue | 40340000 | 39969000 | 0.93 |
| gross profit | 31903000 | 31576000 | 1.04 |
| gross profit ratio | 0.79 | 0.79 | 0.11 |
| research and development expenses | 3993000 | 4352000 | -8.25 |
| operating expenses | 39536000 | 41654000 | -5.08 |
| interest income | 1936000 | 2015000 | -3.92 |
| interest expense | -884000 | 880000 | -200.45 |
| ebitda | -7633000 | -7067000 | -8.01 |
| ebitdaratio | -0.19 | -0.18 | -7.02 |
| operating income | -7633000 | -10078000 | 24.26 |
| operating income ratio | -0.19 | -0.25 | 24.96 |
| net income | -6575000 | -8939000 | 26.45 |
| net income ratio | -0.16 | -0.22 | 27.12 |
| eps | -0.16 | -0.22 | 27.27 |
Revenue Growth: revenue increased to 40 million in 2024Q3 from 40 million in 2024Q2 representing a change of 0.93%. This indicates a sales growth, which is a positive sign for the company.
Gross Profit: Gross Profit increased to 32 million in 2024Q3 from 32 million in 2024Q2 representing a change of 1.04%. This indicates a sales profitability growth, which is a positive sign for the company.
Operating Expenses: Operating Expenses decreased to 40 million in 2024Q3 from 42 million in 2024Q2 representing a change of -5.08%. The decrease in operating expenses can be attributed to various factors such as improved profitability, cost optimization and financial stability, lower operating expenses can be positive indicators.
EBITDA: EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) increased to -8 million in 2024Q3 from -7 million in 2024Q2 representing a change of -8.01%. The increase in EBITDA indicates improved operational efficiency and profitability.
Operating Income: Operating income increased to -8 million in 2024Q3 from -10 million in 2024Q2 representing a change of 24.26%. The increase in operating income indicates better operational performance and increased profitability.
Earnings per Share (EPS): EPS increased to -0.16 in 2024Q3 from -0.16 in 2024Q2 representing a change of 27.27%. This indicates that the company's earnings are increasing and it is becoming more profitable on a per-share basis.
Research and Development (R&D) Expenses: R&D Expenses decreased to 4 million in 2024Q3 from 4 million in 2024Q2 representing a change of -8.25%. This shows that the company decreased investment in innovation and product development, which is not a good sign for long-term growth.
Net Income: Net income decreased to -7 million in 2024Q3 from -9 million in 2024Q2 representing a change of 26.45%. The decrease in net income shows worsen profitability and indicates that the company is generating less profit for each dollar of revenue.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0001459839 | |||
| total assets | 230425000 | 157552000 | 46.25 |
| total liabilities | 61050000 | 59250000 | 3.04 |
| total equity | 169375000 | 98302000 | 72.30 |
| cash and cash equivalents | 33271000 | 20717000 | 60.60 |
| short term investments | 132747999 | 76573000 | 73.36 |
| long term investments | 0 | 0 | NaN |
| total current assets | 211394000 | 137611000 | 53.62 |
| total non current assets | 19031000 | 19941000 | -4.56 |
| total current liabilities | 23456000 | 21178000 | 10.76 |
| total non current liabilities | 37594000 | 38072000 | -1.26 |
| common stock | 4000 | 455175000 | -100.00 |
| retained earnings | -400441000 | -357105000 | -12.14 |
| total debt | 38992000 | 39430000 | -1.11 |
Total Assets: Total Assets increased to 230 million in 2023 from 158 million in 2022 representing a change of 46.25%. Suggesting a growth in asset holdings.
Total Equity: Total Equity increased to 169 million in 2023 from 98 million in 2022 representing a change of 72.3%. This indicates an increase in shareholders' equity.
Cash And Cash Equivalents: Cash And Cash Equivalents increased to 33 million in 2023 from 21 million in 2022 representing a change of 60.6%. This indicates an increase in available liquid assets.
Short Term Investments: Short Term Investments increased to 133 million in 2023 from 77 million in 2022 representing a change of 73.36%. This indicates an increase in short-term investment holdings.
Total Current Assets: Total Current Assets increased to 211 million in 2023 from 138 million in 2022 representing a change of 53.62%. This indicates a better liquidity position.
Total Debt: Total Debt decreased to 39 million in 2023 from 39 million in 2022 representing a change of -1.11%. This indicates a reduction in overall debt burden.
Total Liabilities: Total Liabilities increased to 61 million in 2023 from 59 million in 2022 representing a change of 3.04%. This indicates an increase in overall liabilities.
Total Current Liabilities: Total Current Liabilities increased to 23 million in 2023 from 21 million in 2022 representing a change of 10.76%. This indicates a higher short-term debt burden.
Common Stock: Common Stock decreased to 0 in 2023 from 455 in 2022 representing a change of -100.0%. This indicates a decrease in ownership interest.
Retained Earnings: Retained Earnings decreased to -400 million in 2023 from -357 million in 2022 representing a change of -12.14%. This indicates an accumulated losses.
| 2024Q3 | 2024Q2 | Q/Q change % | |
|---|---|---|---|
| 0001459839 | |||
| total assets | 226998000 | 223843000 | 1.41 |
| total liabilities | 62024000 | 59110000 | 4.93 |
| total equity | 164974000 | 164733000 | 0.15 |
| cash and cash equivalents | 30225000 | 25577000 | 18.17 |
| short term investments | 120593000 | 125950000 | -4.25 |
| long term investments | 0 | 0 | NaN |
| total current assets | 203699000 | 202333000 | 0.68 |
| total non current assets | 23299000 | 21510000 | 8.32 |
| total current liabilities | 24684000 | 22060000 | 11.89 |
| total non current liabilities | 37340000 | 37050000 | 0.78 |
| common stock | 4000 | 4000 | 0.00 |
| retained earnings | -426859000 | -420284000 | -1.56 |
| total debt | 38537000 | 38420000 | 0.30 |
Total Assets: Total Assets increased to 227 million in 2024Q3 from 224 million in 2024Q2 representing a change of 1.41%. Suggesting a growth in asset holdings.
Total Equity: Total Equity increased to 165 million in 2024Q3 from 165 million in 2024Q2 representing a change of 0.15%. This indicates an increase in shareholders' equity.
Cash And Cash Equivalents: Cash And Cash Equivalents increased to 30 million in 2024Q3 from 26 million in 2024Q2 representing a change of 18.17%. This indicates an increase in available liquid assets.
Total Current Assets: Total Current Assets increased to 204 million in 2024Q3 from 202 million in 2024Q2 representing a change of 0.68%. This indicates a better liquidity position.
Total Liabilities: Total Liabilities increased to 62 million in 2024Q3 from 59 million in 2024Q2 representing a change of 4.93%. This indicates an increase in overall liabilities.
Short Term Investments: Short Term Investments decreased to 121 million in 2024Q3 from 126 million in 2024Q2 representing a change of -4.25%. This indicates a decrease in short-term investment holdings.
Total Current Liabilities: Total Current Liabilities increased to 25 million in 2024Q3 from 22 million in 2024Q2 representing a change of 11.89%. This indicates a higher short-term debt burden.
Retained Earnings: Retained Earnings decreased to -427 million in 2024Q3 from -420 million in 2024Q2 representing a change of -1.56%. This indicates an accumulated losses.
Total Debt: Total Debt increased to 39 million in 2024Q3 from 38 million in 2024Q2 representing a change of 0.3%. This indicates an increase in overall debt burden.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0001459839 | |||
| net change in cash | 12554000 | -42702000 | 129.40 |
| operating cash flow | -18713000 | -41655000 | 55.08 |
| free cash flow | -26512000 | -51162000 | 48.18 |
| capital expenditure | -7799000 | -9507000 | 17.97 |
| depreciation and amortization | 5428000 | 3452000 | 57.24 |
| deferred income tax | 0 | 0 | NaN |
| stock based compensation | 24057000 | 23061000 | 4.32 |
| accounts payables | -1118000 | 2529000 | -144.21 |
| inventory | -4719000 | -5709000 | 17.34 |
| acquisitions net | 0 | 0 | NaN |
| investments in property plant and equipment | -7799000 | -9507000 | 17.97 |
| net cash used for investing activites | -59798000 | -2815000 | -2,024.26 |
| debt repayment | 725000 | 0 | NaN |
| common stock issued | 83671000 | 2197000 | 3,708.42 |
| common stock repurchased | 0 | 1818000 | -100.00 |
| dividends paid | 0 | 0 | NaN |
| net cash used provided by financing activities | 90933000 | 2197000 | 4,038.96 |
| cash at end of period | 33271000 | 20717000 | 60.60 |
| accounts receivables | -2122000 | -6479000 | 67.25 |
| cash at beginning of period | 20717000 | 63419000 | -67.33 |
Net Change in Cash: Net Change in Cash increased to 13 million in 2023 from -43 million in 2022 representing a change of 129.4%. Indicating an increased ability to generate cash from the company's operations or its cash flow position.
Operating Cash Flow: Operating Cash Flow increased to -19 million in 2023 from -42 million in 2022 representing a change of 55.08%. This indicates that the company generated more cash from its core business operations.
Free Cash Flow: Free Cash Flow increased to -27 million in 2023 from -51 million in 2022 representing a change of 48.18%. This indicates an increase in cash generated after accounting for capital expenditures.
Accounts Payables: The absolute value of Accounts Payables decreased to 1 million in 2023 from 3 million in 2022 representing a change of -144.21%. This indicates that the company has reduced its outstanding obligations to its suppliers.
Capital Expenditure: Capital Expenditure increased to -8 million in 2023 from -10 million in 2022 representing a change of 17.97%. This indicates an increase in the cash outflow required for acquiring or improving long-term assets.
Stock-Based Compensation: Stock-Based Compensation increased to 24 million in 2023 from 23 million in 2022 representing a change of 4.32%. This indicates increased expenses, which is generally considered a negative sign from a financial perspective.
Accounts Receivables: Accounts Receivables increased to -2 in 2023 from -6 million in 2022 representing a change of 67.25%. This suggests that the company is less capable of collecting payments from its customers.
| 2024Q3 | 2024Q2 | Q/Q change % | |
|---|---|---|---|
| 0001459839 | |||
| operating cash flow | 302000 | -6334000 | 104.77 |
| free cash flow | -2734000 | -9447000 | 71.06 |
| capital expenditure | -3036000 | -3113000 | 2.47 |
| depreciation and amortization | -3169000 | 992000 | -419.46 |
| deferred income tax | 0 | 0 | NaN |
| stock based compensation | 6306000 | 6398000 | -1.44 |
| accounts receivables | -282000 | -2826000 | 90.02 |
| accounts payables | -71000 | -543000 | 86.92 |
| inventory | 3932000 | -2542000 | 254.68 |
| acquisitions net | 0 | 0 | NaN |
| investments in property plant and equipment | -3036000 | -3113000 | 2.47 |
| net cash used for investing activites | 3769000 | -1830000 | 305.96 |
| debt repayment | 0 | 0 | NaN |
| common stock issued | -1881000 | 1776000 | -205.91 |
| common stock repurchased | 1472000 | 0 | NaN |
| dividends paid | 0 | 0 | NaN |
| net cash used provided by financing activities | 155000 | 1776000 | -91.27 |
| net change in cash | 4648000 | -6463000 | 171.92 |
| cash at end of period | 30225000 | 25577000 | 18.17 |
| cash at beginning of period | 25577000 | 32040000 | -20.17 |
Net Change in Cash: Net Change in Cash increased to 5 million in 2024Q3 from -6 million in 2024Q2 representing a change of 171.92%. Indicating an increased ability to generate cash from the company's operations or its cash flow position.
Operating Cash Flow: Operating Cash Flow increased to 0 million in 2024Q3 from -6 million in 2024Q2 representing a change of 104.77%. This indicates that the company generated more cash from its core business operations.
Free Cash Flow: Free Cash Flow increased to -3 million in 2024Q3 from -9 million in 2024Q2 representing a change of 71.06%. This indicates an increase in cash generated after accounting for capital expenditures.
Stock-Based Compensation: Stock-Based Compensation decreased to 6 million in 2024Q3 from 6 million in 2024Q2 representing a change of -1.44%. This indicates decreased expenses, which is generally considered a positive sign from a financial perspective.
Accounts Payables: The absolute value of Accounts Payables decreased to 0 million in 2024Q3 from 1 million in 2024Q2 representing a change of 86.92%. This indicates that the company has reduced its outstanding obligations to its suppliers.
Capital Expenditure: Capital Expenditure increased to -3 million in 2024Q3 from -3 million in 2024Q2 representing a change of 2.47%. This indicates an increase in the cash outflow required for acquiring or improving long-term assets.
Accounts Receivables: Accounts Receivables increased to 0 in 2024Q3 from -3 million in 2024Q2 representing a change of 90.02%. This suggests that the company is less capable of collecting payments from its customers.
We save you time by utilizing Generative AI to summarize earnings transcripts. Our summaries provide a clear insight into the company's current performance, future outlook, and overall sentiment expressed during the call. Click on below links to explore more.
Note: The years mentioned below are fiscal years in accounting.
Q3 2024 Earnings call transcript
EPS represents the portion of a company's profit allocated to each outstanding share of common stock. A higher EPS is generally favorable, indicating stronger profitability on a per-share basis.
Positive EPS: A positive EPS signifies that a company is profitable, it is generally viewed positively, supporting stock value and investor confidence.
Negative EPS: Indicates that a company is operating at a loss, which could lead to negative sentiment, potential stock depreciation, and concerns about the company's financial health.
The Next Earning Date represents when the company plans to release its next set of financial results.
An upward trend in EPS suggests consistent growth in earnings, often leading to increased investor confidence. A downward trend may indicate a decline in earnings, potentially decreasing investor confidence and stock value. Fluctuating EPS suggests unpredictable financial performance, warranting cautious investor analysis.
Earnings surprise occurs when a company's actual earnings differ from analysts' expectations. A positive earnings surprise typically reflects better-than-expected performance, potentially leading to stock appreciation. Conversely, a negative earnings surprise can result in stock depreciation. An earnings surprise of zero means the earnings met expectations, which typically has a neutral impact on stock price.
Discover detailed analyst recommendations for stocks, including categories such as Buy, Hold, Sell, Strong Buy, and Strong Sell. These insights are based on thorough analysis of financial and market factors. The consensus is calculated by assigning a numerical score to each recommendation. These scores are then weighted and averaged over a specified period to provide a comprehensive view of the stock's outlook, with the final score determining the overall consensus.
| 2023-12-31 | 2022-12-31 | Y/Y change % | |
|---|---|---|---|
| FY | |||
| calendar year | 2023 | 2022 | NaN |
| revenue per share | 3.61 | 3.11 | 16.17 |
| net income per share | -1.13 | -1.84 | 38.68 |
| operating cash flow per share | -0.49 | -1.22 | 60.02 |
| free cash flow per share | -0.69 | -1.5 | 53.88 |
| cash per share | 4.32 | 2.84 | 51.88 |
| book value per share | 4.41 | 2.87 | 53.35 |
| tangible book value per share | 4.41 | 2.87 | 53.35 |
| shareholders equity per share | 4.41 | 2.87 | 53.35 |
| interest debt per share | 1.07 | 1.24 | -13.75 |
| market cap | 806591524.81 | 465144806.4 | 73.41 |
| enterprise value | 812312524.81 | 483857806.4 | 67.88 |
| pe ratio | -18.61 | -7.39 | -151.70 |
| price to sales ratio | 5.81 | 4.37 | 32.86 |
| pocfratio | -43.1 | -11.17 | -286.00 |
| pfcf ratio | -30.42 | -9.09 | -234.63 |
| pb ratio | 4.76 | 4.73 | 0.64 |
| ptb ratio | 4.76 | 4.73 | 0.64 |
| ev to sales | 5.85 | 4.55 | 28.62 |
| enterprise value over ebitda | -23.58 | -8.8 | -167.99 |
| ev to operating cash flow | -43.41 | -11.62 | -273.71 |
| ev to free cash flow | -30.64 | -9.46 | -223.97 |
| earnings yield | -0.05 | -0.14 | 60.27 |
| free cash flow yield | -0.03 | -0.11 | 70.12 |
| debt to equity | 0.22 | 0.4 | -44.83 |
| debt to assets | 0.16 | 0.25 | -35.01 |
| net debt to ebitda | -0.17 | -0.34 | 51.20 |
| current ratio | 9.01 | 6.5 | 38.70 |
| interest coverage | -13.56 | -21.15 | 35.89 |
| income quality | 0.43 | 0.68 | -36.50 |
| dividend yield | 0 | 0 | NaN |
| payout ratio | 0 | 0 | NaN |
| sales general and administrative to revenue | 0.22 | 0.27 | -17.80 |
| research and ddevelopement to revenue | 0.11 | 0.13 | -15.51 |
| intangibles to total assets | 0 | 0 | NaN |
| capex to operating cash flow | -0.42 | -0.23 | -82.61 |
| capex to revenue | 0.06 | 0.09 | -37.15 |
| capex to depreciation | 1.44 | 2.75 | -47.83 |
| stock based compensation to revenue | 0.17 | 0.22 | -20.07 |
| graham number | 10.58 | 10.91 | -3.03 |
| roic | -0.23 | -0.44 | 48.95 |
| return on tangible assets | -0.19 | -0.4 | 52.89 |
| graham net net | 3.42 | 1.82 | 88.29 |
| working capital | 187938000 | 116433000 | 61.41 |
| tangible asset value | 169375000 | 98302000 | 72.30 |
| net current asset value | 150344000 | 78361000 | 91.86 |
| invested capital | 206644000 | 135999000 | 51.95 |
| average receivables | 21313500 | 17460000 | 22.07 |
| average payables | 5433500 | 4738500 | 14.67 |
| average inventory | 18765500 | 14390000 | 30.41 |
| days sales outstanding | 57.69 | 70.92 | -18.64 |
| days payables outstanding | 56.83 | 145.93 | -61.06 |
| days of inventory on hand | 250.83 | 401.65 | -37.55 |
| receivables turnover | 6.33 | 5.15 | 22.92 |
| payables turnover | 6.42 | 2.5 | 156.77 |
| inventory turnover | 1.46 | 0.91 | 60.13 |
| roe | -0.26 | -0.64 | 60.02 |
| capex per share | 0.2 | 0.28 | -26.99 |
ROE: Return on Equity (ROE) increased to -0.26 on 2023-12-31 from -0.64 on 2022-12-31, representing a change of 60.02%. However, ROE is <= 5%, suggesting that the company has not been generating high returns for its shareholders.
PE Ratio: Price-to-Earnings (P/E) Ratio decreased to -18.61 on 2023-12-31 from -7.39 on 2022-12-31, representing a change of -151.70%. Indicating a decrease in the relative valuation of the company's stock.
Current Ratio: Current Ratio increased to 9.01 on 2023-12-31 from 6.50 on 2022-12-31, representing a change of 38.70%. The current ratio has been increasing, suggesting an increase in the company's short-term liquidity. Since it's above 3, indicating poor management of working capital.
Debt-to-Equity Ratio: Debt-to-Equity Ratio decreased to 0.22 on 2023-12-31 from 0.40 on 2022-12-31, representing a change of -44.83%. The debt-to-equity ratio has been decreasing, indicating that the company has been relying less on debt financing. A ratio of 1 or below is often considered healthy and indicates that the company's total debt is equal to or less than its total equity.
| 2024-09-30 Q3 | 2024-06-30 Q2 | Q/Q change % | |
|---|---|---|---|
| SIBN | |||
| calendar year | 2024 | 2024 | NaN |
| revenue per share | 0.97 | 0.97 | -0.04 |
| net income per share | -0.16 | -0.22 | 27.15 |
| operating cash flow per share | 0.01 | -0.15 | 104.72 |
| free cash flow per share | -0.07 | -0.23 | 71.34 |
| cash per share | 3.62 | 3.67 | -1.42 |
| book value per share | 3.95 | 3.99 | -0.81 |
| tangible book value per share | 3.95 | 3.99 | -0.81 |
| shareholders equity per share | 3.95 | 3.99 | -0.81 |
| interest debt per share | 0.9 | 0.9 | 0.71 |
| market cap | 583210719.9 | 532997388.3 | 9.42 |
| enterprise value | 591522719.9 | 545840388.3 | 8.37 |
| pe ratio | -22.18 | -14.91 | -48.76 |
| price to sales ratio | 14.46 | 13.34 | 8.41 |
| pocfratio | 1931.16 | -84.15 | 2,394.94 |
| pfcf ratio | -213.32 | -56.42 | -278.09 |
| pb ratio | 3.54 | 3.24 | 9.26 |
| ptb ratio | 3.54 | 3.24 | 9.26 |
| ev to sales | 14.66 | 13.66 | 7.37 |
| enterprise value over ebitda | -77.5 | -77.24 | -0.33 |
| ev to operating cash flow | 1958.68 | -86.18 | 2,372.88 |
| ev to free cash flow | -216.36 | -57.78 | -274.46 |
| earnings yield | -0.01 | -0.02 | 32.78 |
| free cash flow yield | -0.0 | -0.02 | 73.55 |
| debt to equity | 0.23 | 0.22 | 6.45 |
| debt to assets | 0.17 | 0.16 | 5.12 |
| net debt to ebitda | -1.09 | -1.82 | 40.08 |
| current ratio | 8.25 | 9.17 | -10.03 |
| interest coverage | 8.63 | -11.45 | 175.40 |
| income quality | -0.05 | 0.71 | -106.48 |
| dividend yield | 0 | 0 | NaN |
| payout ratio | 0 | 0 | NaN |
| sales general and administrative to revenue | 0.2 | 0.21 | -3.74 |
| research and ddevelopement to revenue | 0.1 | 0.11 | -9.09 |
| intangibles to total assets | 0 | 0 | NaN |
| capex to operating cash flow | 10.05 | -0.49 | 2,145.47 |
| capex to revenue | 0.08 | 0.08 | -3.37 |
| capex to depreciation | -0.96 | 3.14 | -130.53 |
| stock based compensation to revenue | 0.16 | 0.16 | -2.34 |
| graham number | 3.74 | 4.41 | -15.00 |
| roic | -0.04 | -0.05 | 25.24 |
| return on tangible assets | -0.03 | -0.04 | 27.47 |
| graham net net | 2.88 | 2.97 | -2.89 |
| working capital | 179015000 | 180273000 | -0.70 |
| tangible asset value | 164974000 | 164733000 | 0.15 |
| net current asset value | 141675000 | 143223000 | -1.08 |
| invested capital | 201988000 | 201460000 | 0.26 |
| average receivables | 24852500 | 23452500 | 5.97 |
| average payables | 7249000 | 7420500 | -2.31 |
| average inventory | 24375500 | 22141000 | 10.09 |
| days sales outstanding | 55.57 | 55.83 | -0.47 |
| days payables outstanding | 78.06 | 76.99 | 1.39 |
| days of inventory on hand | 272.21 | 249.13 | 9.26 |
| receivables turnover | 1.62 | 1.61 | 0.47 |
| payables turnover | 1.15 | 1.17 | -1.37 |
| inventory turnover | 0.33 | 0.36 | -8.48 |
| roe | -0.04 | -0.05 | 26.55 |
| capex per share | 0.07 | 0.08 | -3.41 |
ROE: Return on Equity (ROE) increased to -0.04 on 2024-09-30 Q3 from -0.05 on 2024-06-30 Q2, representing a change of 26.55%. However, ROE is <= 5%, suggesting that the company has not been generating high returns for its shareholders.
PE Ratio: Price-to-Earnings (P/E) Ratio decreased to -22.18 on 2024-09-30 Q3 from -14.91 on 2024-06-30 Q2, representing a change of -48.76%. Indicating a decrease in the relative valuation of the company's stock.
Current Ratio: Current Ratio decreased to 8.25 on 2024-09-30 Q3 from 9.17 on 2024-06-30 Q2, representing a change of -10.03%. The current ratio has been declining, suggesting a decrease in the company's short-term liquidity. Since it's above 3, indicating poor management of working capital.
Debt-to-Equity Ratio: Debt-to-Equity Ratio increased to 0.23 on 2024-09-30 Q3 from 0.22 on 2024-06-30 Q2, representing a change of 6.45%. The debt-to-equity ratio has been increasing, indicating that the company has been relying more on debt financing. Higher leverage may increase financial risk. However, a ratio of 1 or below is often considered healthy and indicates that the company's total debt is equal to or less than its total equity.
None
| Market Capitalization | Enterprise Value | |
|---|---|---|
| Definition | The total market value of a company's outstanding shares | The total market value of a company, including its debt and other liabilities |
| Calculation | Current share price * Total number of outstanding shares | Market capitalization + Total debt - Cash and cash equivalents |
| Focus | Equity component of a company's value | Total economic value of a company |
| Usefulness | Assesses a company's size and growth potential based on investor sentiment | Provides a more comprehensive valuation that considers both equity and debt |
Analyzing dividends is a crucial aspect of investment evaluation, offering valuable insights into a company's financial health and its commitment to shareholder returns. Dividends represent a portion of a company's profits distributed to its shareholders, providing a steady income stream. We help you analyze dividends based on the indicators mentioned below:
• Investors often assess the average dividend amount, observing trends over time to gauge the company's stability and growth potential. A positive trend in average dividends indicates a consistent and potentially lucrative investment. Additionally, evaluating the trend of dividend increases provides insight into the company's financial strength and management's confidence in future earnings.
• Consistency in paying dividends is a reassuring sign, reflecting a company's reliability and commitment to shareholder value. For investors, dividends not only offer income but also contribute to the overall total return on investment.
• Companies with a history of regular and increasing dividends can attract income-focused investors seeking stable returns, making dividends a critical factor in building a well-rounded investment portfolio.
Interested in the overall sentiment for a particular period? Check out our news sentiment analysis tool.
Sentiment: Positive
Publish Date: 2024-11-12 22:42:29
SI-BONE, Inc. (NASDAQ:SIBN ) Q3 2024 Earnings Conference Call November 12, 2024 4:30 PM ET Company Participants Saqib Iqbal - Senior Director of Investor Relations Laura Francis - Chief Executive Officer Anshul Maheshwari - Chief Financial Officer Conference Call Participants Craig Bijou - BofA Securities Young Li - Jefferies Drew Ranieri - Morgan Stanley Caitlin Cronin - Canaccord Richard Newitter - Truist Securities Operator Good afternoon, and welcome to SI-BONE's Third Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.
Sentiment: Negative
Publish Date: 2024-11-12 18:26:08
Si-Bone (SIBN) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.22. This compares to loss of $0.25 per share a year ago.
Sentiment: Positive
Publish Date: 2024-11-12 16:09:00
SANTA CLARA, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq:SIBN), a medical device company dedicated to solving sacropelvic disorders, today reported financial results for the quarter ended September 30, 2024.
Sentiment: Neutral
Publish Date: 2024-11-05 08:30:00
The iFuse Bedrock Granite™ system is a Breakthrough Device Designation technology that provides pelvic fixation and sacroiliac joint fusion, in conjunction with lumbar spinal fusion procedures The iFuse Bedrock Granite™ system is a Breakthrough Device Designation technology that provides pelvic fixation and sacroiliac joint fusion, in conjunction with lumbar spinal fusion procedures
Sentiment: Positive
Publish Date: 2024-10-30 04:35:19
Si-Bone (SIBN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Sentiment: Positive
Publish Date: 2024-10-22 16:09:00
SANTA CLARA, Calif., Oct. 22, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced it will report financial results for the third quarter of 2024 after market close on Tuesday, November 12, 2024. Management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Sentiment: Positive
Publish Date: 2024-10-14 13:20:22
SI-BONE aims to address the unmet clinical needs of complex pelvic fragility fractures by providing a solution that improves both surgical efficiency and patient recovery.
Sentiment: Positive
Publish Date: 2024-10-10 08:30:00
SANTA CLARA, Calif., Oct. 10, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a Silicon Valley-based medical device company dedicated to providing surgical solutions for sacropelvic disorders, today announced first-in-patient procedures with the FDA-designated breakthrough device, iFuse TORQ TNT™ Implant System (TNT). Designed to address the anatomic and biomechanical challenges of pelvic fragility fractures, particularly in patients with poor bone quality, TNT offers a significant advancement over traditional cannulated screws.
Sentiment: Positive
Publish Date: 2024-08-26 10:55:30
The average of price targets set by Wall Street analysts indicates a potential upside of 40.3% in Si-Bone (SIBN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Sentiment: Positive
Publish Date: 2024-08-26 09:20:21
SI-BONE (SIBN) receives FDA 510(k) clearance for its iFuse TORQ TNT implant system, followed by a Breakthrough Device Designation award by the FDA.
Sentiment: Positive
Publish Date: 2024-08-22 16:30:00
SANTA CLARA, Calif., Aug. 22, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced that the company will be participating in the upcoming Morgan Stanley 22nd Annual Global Healthcare Conference in New York. Management will be hosting a fireside chat on Wednesday, September 4, 2024, at 10:45 a.m. Eastern Time / 7:45 a.m. Pacific Time.
Sentiment: Positive
Publish Date: 2024-08-20 08:30:00
SANTA CLARA, Calif., Aug. 20, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc., (Nasdaq: SIBN), a Silicon Valley-based medical device company dedicated to providing surgical solutions for sacropelvic disorders, announces FDA 510(k) clearance of the iFuse TORQ TNT™ Implant System (TNT). The TNT implant system is designed to meet the specific anatomical and bone mineral density needs of the sacrum and ilium and will serve as the next generation technology for pelvic fragility fracture fixation and sacroiliac joint fusion.
* The sentiment analysis presented is generated through an algorithm and may be subject to inaccuracies. Users are advised to corroborate key information and employ further analytical methods prior to making critical decisions.
Get instant AI-powered professional insights:
💡Generate AI Technical Analysis ReportUnderstand the chart below:
Interpret Technical Indicators
| Indicator | Bullish | Bearish |
|---|---|---|
| Price and EMA ⓘ | Price crosses above EMA | Price crosses below EMA |
| Short-Term vs Long-Term EMA ⓘ | Short EMA crosses above Long EMA | Short EMA crosses below Long EMA |
| Volume ⓘ | Increasing volume during price uptrend | Increasing volume during price downtrend |
| MACD ⓘ | MACD crosses above Signal Line | MACD crosses below Signal Line |
| RSI ⓘ | RSI is below 30 (oversold) and starts to rise above 30 | RSI is above 70 (overbought) and starts to decline below 70 |
| Candlestick Patterns ⓘ | Bullish candlestick patterns | Bearish candlestick patterns |
Copyright © 2024 Sirius Investors
All rights reserved
